• 1 November 2017

    Is there a bright pharma future for friendly bacteria?

    As mainstream consumer products, probiotics are often thought of as modestly effective at best, and are typically restricted to aiding gastrointestinal function. However, new research points to many more diverse...

  • 18 October 2017

    Tenapanor likely to makes waves in IBS-C space

    On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety of its lead product, tenapanor, which is under development for...


Go Top